Read by QxMD icon Read

Breast Cancer Research and Treatment

April Phantana-Angkool, Meghan R Forster, Yancey E Warren, Chad A Livasy, Amy H Sobel, Lakesha M Beasley, Sally J Trufan, Lejla Hadzikadic-Gusic, Terry Sarantou, Amy E Voci, Deba Sarma, Richard L White
PURPOSE: Radial scars (RS) commonly present mammographically as architectural distortions, but these lesions may be associated with non-invasive and invasive breast cancer. Digital breast tomosynthesis (DBT) has resulted in higher detection rates of architectural distortion particularly in patients with dense breast tissue. We hypothesized that rates of clinically relevant lesions confirmed surgically would be lower in patients who received DBT imaging compared with those who received standard digital breast imaging...
September 21, 2018: Breast Cancer Research and Treatment
Anamika Bhargava, Sumit Saha
PURPOSE: The purpose of this review article is to discuss the potential of T-type voltage gated calcium channels (VGCCs) as drug targets in breast cancer. Breast cancer, attributable to the different molecular subtypes, has a crucial need for therapeutic strategies to counter the mortality rate. VGCCs play an important role in regulating cytosolic free calcium levels which regulate cellular processes like tumorigenesis and cancer progression. In the last decade, T-type VGCCs have been investigated in breast cancer proliferation...
September 21, 2018: Breast Cancer Research and Treatment
Y Shen, T Fujii, N T Ueno, D Tripathy, N Fu, H Zhou, J Ning, L Xiao
BACKGROUND: Trastuzumab (H) with chemotherapy benefits patients with HER2+ breast cancer (BC); however, we lack head-to-head pairwise assessment of survival or cardiotoxicity for specific combinations. We sought to identify optimal combinations. METHODS: We searched PubMed, updated October 2017, using keywords "Breast Neoplasms/drug therapy," "Trastuzumab," and "Clinical Trial" and searched Cochrane Library. Our search included randomized trials of adjuvant H plus chemotherapy for early-stage HER2+ BC, and excluding trials of neoadjuvant therapy or without data to obtain hazard ratios (HRs) for outcomes...
September 21, 2018: Breast Cancer Research and Treatment
Hiroji Iwata, Norikazu Masuda, Yutaka Yamamoto, Tomomi Fujisawa, Tatsuya Toyama, Masahiro Kashiwaba, Shoichiro Ohtani, Naruto Taira, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Yukiko Shibahara, Hironobu Sasano, Takuhiro Yamaguchi, Kentaro Sakamaki, Helen Bailey, Diana B Cherbavaz, Debbie M Jakubowski, Naoko Sugiyama, Calvin Chao, Yasuo Ohashi
PURPOSE: The Recurrence Score test is validated to predict benefit of adjuvant chemotherapy. TransNEOS, a translational study of New Primary Endocrine-therapy Origination Study (NEOS), evaluated whether Recurrence Score results can predict clinical response to neoadjuvant letrozole. METHODS: NEOS is a phase 3 clinical trial of hormonal therapy ± adjuvant chemotherapy for postmenopausal patients with ER+, HER2-negative, clinically node-negative breast cancer, after six months of neoadjuvant letrozole and breast surgery...
September 21, 2018: Breast Cancer Research and Treatment
Enoch Chang, Sarah S Mougalian, Kerin B Adelson, Melissa R Young, James B Yu
PURPOSE: The prevalence of patients living with prolonged interval between initial breast cancer diagnosis and development of subsequent metastatic disease may be increasing with improved treatment. In order to counsel these patients as to their prognosis, we investigated the association between metastatic free interval (MFI) and subsequent survival from newly diagnosed metastatic breast cancer (MBC) in a population-level U.S. cohort. METHODS: The Surveillance, Epidemiology and End Results database was used to identify patients with both an initial stage 1-3 breast cancer diagnosis and subsequent MBC diagnosis recorded from 1988 to 2014...
September 21, 2018: Breast Cancer Research and Treatment
Francisco Acevedo, V Diego Armengol, Zhengyi Deng, Rong Tang, Suzanne B Coopey, Danielle Braun, Adam Yala, Regina Barzilay, Clara Li, Amy Colwell, Anthony Guidi, Curtis L Cetrulo, Judy Garber, Barbara L Smith, Tari King, Kevin S Hughes
PURPOSE: Mammoplasty removes random samples of breast tissue from asymptomatic women providing a unique method for evaluating background prevalence of breast pathology in normal population. Our goal was to identify the rate of atypical breast lesions and cancers in women of various ages in the largest mammoplasty cohort reported to date. METHODS: We analyzed pathologic reports from patients undergoing bilateral mammoplasty, using natural language processing algorithm, verified by human review...
September 20, 2018: Breast Cancer Research and Treatment
Se Kyung Lee, Seok Won Kim, Jong-Han Yu, Jeong Eon Lee, Ji Young Kim, Joohyun Woo, Seokwon Lee, Eun-Kyu Kim, Hyeong-Gon Moon, Sung Sang Ko, Seok Jin Nam
PURPOSE: Women with breast cancer in Asian and Western countries are similar in many respects, but there are also differences, such as in the age at onset and the proportion of breast cancer occurring at younger ages. There is controversy as to whether these differences are due to inter-racial genetic differences or to environmental or other factors. METHODS: Using the Korean Breast Cancer Society's large breast cancer registry, we investigated the causes of Koreans' unique breast cancer characteristics by examining the changes in the incidence and proportion of young-onset breast cancer (YBC) in Korea over time...
September 20, 2018: Breast Cancer Research and Treatment
Gilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, Jean-Marc Classe, Fabien Reyal, Chafika Mazouni, Nicolas Chopin, Alejandra Martinez, Emile Daraï, Charles Coutant, Pierre-Emmanuel Colombo, Pierre Gimbergues, Marie-Pierre Chauvet, Anne-Sophie Azuar, Roman Rouzier, Christine Tunon de Lara, Xavier Muracciole, Aubert Agostini, Anthony Gonçalves, Eric Lambaudie
BACKGROUND: Tumour features associated with isolated invasive breast cancer (BC) ipsilateral local recurrence (ILR) after breast conservative treatment (BCT) and consequences on overall survival (OS) are still debated. Our objective was to investigate these points. METHODS: Patients were retrospectively identified from a cohort of patients who underwent BCT for invasive BC in 16 cancer centres. End-points were ILR rate and OS. The impact of ILR on OS was assessed by multivariate analysis (MVA) for all patients and according to endocrine receptors (ERs) and grade or tumour subtypes...
September 20, 2018: Breast Cancer Research and Treatment
Saroj Niraula, Bishal Gyawali
BACKGROUND: One year of adjuvant trastuzumab, chosen empirically, improves survival of women with early-stage, Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Two years of trastuzumab does not improve efficacy but increases cost, inconvenience, and adverse effects. We aimed to evaluate if less than 1 year of adjuvant trastuzumab retained efficacy while reducing toxicities and cost. METHODS: We performed a pooled analyses of efficacy and toxicity from Randomized Controlled Trials (RCTs) comparing 1 year of trastuzumab to shorter durations in adjuvant treatment of HER2-positive breast cancer...
September 20, 2018: Breast Cancer Research and Treatment
Joan M Neuner, Amanda Kong, Ann Blaes, Danielle Riley, Elizabeth Chrischilles, Alicia Smallwood, Ingrid Lizarraga, Mary Schroeder
BACKGROUND: There are advantages to neoadjuvant chemotherapy in operable breast cancer, particularly for those with higher-risk cancers, but little is known about factors that are associated with the use of neoadjuvant chemotherapy outside of clinical trials. We examined whether use of neoadjuvant chemotherapy instead of adjuvant chemotherapy varies by nonclinical factors such as patient socioeconomic status or rural residence. METHODS: Women diagnosed with breast cancer in 2013-2014 at eight medical institutions were surveyed by mail regarding their experiences with breast cancer treatment, and this information was linked to hospital-based cancer registries...
September 19, 2018: Breast Cancer Research and Treatment
Wei Lue Tong, Blake M Callahan, Yaping N Tu, Saif Zaman, Boris I Chobrutskiy, George Blanck
PURPOSE: Immune characterizations of cancers, including breast cancer, have led to information useful for prognoses and are considered to be important in the future of refining the use of immunotherapies, including immune checkpoint inhibitor therapies. In this study, we sought to extend these characterizations with genomics approaches, particularly with cost-effective employment of exome files. METHODS: By recovery of immune receptor recombination reads from the cancer genome atlas (TCGA) breast cancer dataset, we observed associations of these recombinations with T-cell and B-cell biomarkers and with distinct survival rates...
September 18, 2018: Breast Cancer Research and Treatment
David M McClatchy, Rebecca A Zuurbier, Wendy A Wells, Keith D Paulsen, Brian W Pogue
BACKGROUND: Roughly 23% of breast conserving surgery (BCS) patients undergo a second re-excision procedure due to pathologically positive surgical margins. We investigated the feasibility and potential value of micro-Computed Tomography (micro-CT) as a surgical margin guidance tool during BCS. METHODS: A cohort of 32 BCS specimens was prospectively imaged with a pre-clinical micro-CT system upon arrival in the surgical pathology laboratory. Reconstructed micro-CT scans were evaluated retrospectively by an experienced breast radiologist, who provided binary determinations whether lesions extended to the specimen margin...
September 17, 2018: Breast Cancer Research and Treatment
Claudette Falato, Sara K Taylor, Robert Szulkin, Axel Nordblom, Louise Eriksson, Anastasios Sofiadis, Irma Fredriksson, Johan Hartman, Jonas Bergh, Theodoros Foukakis
RATIONALE: Survival after loco-regional failure (LRF) of breast cancer was investigated at the population level. METHODS: Using the Stockholm cancer registry, 2698 patients diagnosed with LRF between 1980 and 2014 were identified and divided into three cohorts by year of LRF diagnosis. Post-relapse event-free survival (EFS) and overall survival (OS) were analyzed separately in local and loco-regional relapses and compared across the cohorts by Kaplan-Meier method...
September 17, 2018: Breast Cancer Research and Treatment
Zhiyang Liu, Zeyad Sahli, Yongchun Wang, Antonio C Wolff, Leslie M Cope, Christopher B Umbricht
PURPOSE: Although age is a recognized independent prognostic risk factor, its relative importance among molecular subtypes of Breast cancer (BCA) is not well documented. The aim of this study was to evaluate the prognostic role of age at diagnosis among different immunohistochemical subtypes of BCA. METHODS: We conducted a retrospective study of women with invasive BCA undergoing surgery at the Johns Hopkins Hospital, excluding patients presenting with stage IV breast cancer...
September 17, 2018: Breast Cancer Research and Treatment
Laura Spring, Andrzej Niemierko, Stephanie Haddad, Megan Yuen, Amy Comander, Kerry Reynolds, Jennifer Shin, Atul Bahn, Elena Brachtel, Michelle Specht, Barbara L Smith, Alphonse Taghian, Rachel Jimenez, Jeffrey Peppercorn, Steven J Isakoff, Beverly Moy, Aditya Bardia
PURPOSE: Based on improvement in pathologic complete response (pCR) in the NeoSphere and TRYPHAENA studies, the FDA approved neoadjuvant pertuzumab for HER2+ localized breast cancer. These studies demonstrated high pCR rates with THP (docetaxel + HP), FEC (5-fluorouracil, epirubicin, and cyclophosphamide)-THP, and TCHP (docetaxel, carboplatin + HP). However, in the United States, doxorubicin/cyclophosphamide (AC) is favored over FEC despite no data comparing neoadjuvant AC-THP with AC-TH or TCHP...
September 15, 2018: Breast Cancer Research and Treatment
Emily R McMullen, Maria E Gonzalez, Stephanie L Skala, Mai Tran, Dafydd Thomas, Sabra I Djomehri, Boris Burman, Kelley M Kidwell, Celina G Kleer
PURPOSE: Metaplastic breast carcinomas are an aggressive subtype of triple-negative breast cancer (TNBC) in which part or all of the adenocarcinoma transforms into a non-glandular component (e.g., spindled, squamous, or heterologous). We discovered that mammary-specific Ccn6/Wisp3 knockout mice develop mammary carcinomas with spindle and squamous differentiation that share upregulation of the oncofetal proteins IGF2BP2 (IMP2) and HMGA2 with human metaplastic carcinomas. Here, we investigated the functional relationship between CCN6, IGF2BP2, and HMGA2 proteins in vitro and in vivo, and their expression in human tissue samples...
September 15, 2018: Breast Cancer Research and Treatment
Jai Min Ryu, Hee Jun Choi, Isaac Kim, Se Kyung Lee, Jonghan Yu, Jee-Eun Kim, Byeong-Il Kang, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim
PURPOSE: Beginning in 2018, biomarkers including estrogen receptor (ER) status were incorporated in the 8th AJCC staging system. ER expression levels were not considered in these changes. We hypothesized that the levels of ER expression could affect the prognosis of breast cancer. METHODS: A retrospective review was conducted to identify all female patients with invasive breast cancer between 2003 and 2012. ER negative (group I), weakly ER-positive (group II), and strongly ER-positive (group III) were defined as Allred total scores of 0-2, 3-5, and 6-8, respectively...
September 14, 2018: Breast Cancer Research and Treatment
Hussein Khaled, Heba Gamal, Mohamed Lotayef, Michael Knauer, Beat Thürliman
PURPOSE: The theme of the 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria was about seeking where appropriate to escalate or de-escalate therapies for early breast cancer based on the up-to-date information of loco-regional and systemic therapies. Along with this line, a group of Egyptian experts decided to arrange for a consensus session to elicit the differences and similarities in therapy recommendations for early breast cancer in Egypt compared to the original Saint Gallen voting and recommendations...
September 14, 2018: Breast Cancer Research and Treatment
J Oliva-Moreno, L M Peña-Longobardo
BACKGROUND: Breast cancer is one of the most common cancers among women worldwide, and is the most common cause of cancer deaths in them. Given that such disease has a significant impact on middle-aged women, it can result in considerable labour productivity losses. The main objective of this study is therefore to analyse labour productivity losses and years of potential working life lost as a result of premature deaths from breast cancer in Spain over a 10-year period (2005-2014). METHOD: To this end, by combining data on average salary (Salary Structure Survey), occupation (Active Population Survey) and deaths (death registration according to cause of death), a simulation model based on the human capital approach was constructed to estimate productivity losses associated with premature deaths caused by this disease...
September 12, 2018: Breast Cancer Research and Treatment
Seung Hyuck Jeon, Kyung Hwan Shin, Jin Ho Kim, Kyubo Kim, In Ah Kim, Kyung-Hun Lee, Tae-Yong Kim, Seock-Ah Im
PURPOSE: In the present study, the ability of adjuvant trastuzumab to reduce locoregional recurrence in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer receiving adjuvant chemotherapy and radiotherapy (RT) was investigated. MATERIALS AND METHODS: We retrospectively included 520 patients with HER2-overexpressing breast cancer who received surgery followed by adjuvant RT and cytotoxic chemotherapy from 2003 to 2011. Adjuvant trastuzumab was administered to 286 patients...
September 12, 2018: Breast Cancer Research and Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"